Biomerica, Inc. (NASDAQ: BMRA) announced on October 16, 2025 that it has entered into a marketing services agreement with Henry Schein, Inc. (NASDAQ: HSIC) to market its inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State. The partnership will leverage Henry Schein’s extensive distribution network, which includes more than 400 medical field sales and telesales representatives, to promote the test to primary‑care and gastroenterology specialty practices.
Henry Schein, the world’s largest provider of health‑care solutions to office‑based dental and medical practitioners, reported $12 billion in annual sales in 2024 and has a 93‑year history of innovation. By partnering with Biomerica, Henry Schein will add a precision‑diagnostic product that identifies patient‑specific food triggers for IBS, a condition affecting 10‑15% of U.S. adults. The agreement is expected to broaden the test’s reach across a nationwide network of clinicians and potentially increase adoption rates.
For Biomerica, the deal represents a strategic milestone in its commercialization strategy for the inFoods® platform. The company’s CEO, Zack Irani, highlighted that Henry Schein’s national reach and proven track record in delivering innovative medical products will help accelerate adoption of the non‑drug, personalized solution for IBS management. This partnership aligns with Biomerica’s goal of expanding market access and securing payer reimbursement for its diagnostic‑guided therapies.
The inFoods® IBS test has been validated in a multicenter, double‑blinded study published in the June 2025 issue of Gastroenterology, demonstrating statistically significant outcomes in IBS‑M patients. By integrating the test into Henry Schein’s distribution channels, Biomerica aims to translate clinical evidence into real‑world usage, potentially unlocking new revenue streams and strengthening its position in the gastrointestinal diagnostics market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.